Healthcare / BiotechnologyNSE
$917.25
-135.25 (-12.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $23.0M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
72/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.8B
P/E
35.3x
↑EV/EBITDA
24.1x
↑ROE
17.5%
↑Gross Margin
69.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+22.4%
FCF CAGR
—
FCF margin
4.1%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.28B · net income $2.09B · FCF $335.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.28B | $8.28B | $6.96B | $5.57B | $4.51B |
| Net Income | $2.09B | $2.09B | $1.88B | $1.19B | $898.6M |
| EBITDA | $3.05B | $3.05B | $2.71B | $1.85B | $1.37B |
| EPS | 25.98 | 25.98 | 23.35 | 14.80 | 11.16 |
| Gross Margin | 69.3% | 69.3% | 69.7% | 50.0% | 48.9% |
| Operating Margin | 32.1% | 32.1% | 34.5% | 28.3% | 25.6% |
| Net Margin | 25.3% | 25.3% | 27.0% | 21.4% | 19.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Current Ratio | 4.40 | 4.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $335.3M | $335.3M | $23.0M | $-323.5M | $-443.1M |
| Returns | |||||
| ROE | 17.5% | 17.5% | 18.9% | 14.6% | 12.8% |
| Valuation | |||||
| P/E | 35.28 | 35.28 | 30.39 | 25.84 | 18.48 |
| EV/EBITDA | 24.10 | 24.10 | 20.85 | 16.28 | 11.66 |
| P/B | 6.16 | 6.16 | 5.73 | 3.78 | 2.37 |
| Growth & Yield | |||||
| Revenue Growth | 18.9% | 18.9% | 25.0% | 23.6% | — |
| EPS Growth | 11.3% | 11.3% | 57.8% | 32.6% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.3%
EPS terminal req.
$81.39
Spread vs growth
-35.1%
5Y implied EPS CAGR
30.5%
EPS terminal req.
$98.48
Spread vs growth
-19.3%
10Y implied EPS CAGR
19.8%
EPS terminal req.
$158.61
Spread vs growth
-8.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.0%
Start / end P/E
31.0x → 35.3x
EPS bridge
23.35 → 25.98
Residual
+1.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.